Literature DB >> 25307285

Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia.

Mathieu Blot1, Pierre Boyer2, Maxime Samson3, Sylvain Audia3, Hervé Devilliers4, Vanessa Leguy1, Sabine Berthier1, Jean-François Besancenot4, Bernard Lorcerie5, Daniela Lakomy6, Bernard Bonnotte7.   

Abstract

BACKGROUND: Although secondary hypogammaglobulinemia is more frequent than primary hypogammaglobulinemia, its etiology and management are poorly described, particularly for mild hypogammaglobulinemia.
METHODS: This retrospective observational study included all adult patients with a gammaglobulin level <6.4g/L on serum electrophoresis identified at Dijon teaching hospital between April and September 2012. Clinico-biological features, etiologies and infectious complications were collected at inclusion and compared between group 1 (gammaglobulin <5g/L, severe hypogammaglobulinemia), and group 2 (gammaglobulin <6.4 and ≥5g/L, mild hypogammaglobulinemia).
RESULTS: Among the 4011 serum electrophoreses, 570 samples from 389 patients had gammaglobulin levels below 6.4g/L: 156 (40%) in group 1 and 233 (60%) in group 2. Mean age±SD was 67 (15) years, and sex ratio was 1.04 (M/F) with no difference between the two groups. An etiology was identified in 79% and 58% of patients in groups 1 and 2, respectively (p<0.0001). The main etiologies were similar in both groups and included malignant hemopathy treated with cytostatic agents (n=129, 33%), smoldering or newly-diagnosed hemopathy without treatment (n=49, 13%) and immunosuppressive treatment (n=91, 23%). The incidence of hypogammaglobulinemia-related infections was 22/100/year, with no significant difference between the two groups (p=0.17). Vaccination coverage against pneumococcus was 33%, and higher in group 1 (46% vs. 24%; p<0.0001). When no cause was known at inclusion, an etiology was discovered in 22/130 patients (17%), 11 in each group.
CONCLUSIONS: Though mild hypogammaglobulinemia does not meet the classical criteria for hypogammaglobulinemia (<5g/L), the etiology and infectious risk are similar. It therefore requires investigation and vaccination.
Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Etiology; Hypogammaglobulinemia; Infection; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 25307285     DOI: 10.1016/j.ejim.2014.09.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  5 in total

Review 1.  Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Authors:  Ewa Więsik-Szewczyk; Aleksandra Kucharczyk; Katarzyna Świerkocka; Elżbieta Rutkowska; Karina Jahnz-Różyk
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

2.  Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.

Authors:  Andrea Marcinnò; Fabiana Marnetto; Paola Valentino; Serena Martire; Alessia Balbo; Aurora Drago; Maria Leto; Marco Capobianco; Giancarlo Panzica; Antonio Bertolotto
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-13

3.  Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.

Authors:  Nora Möhn; Steffen Pfeuffer; Tobias Ruck; Catharina C Gross; Thomas Skripuletz; Luisa Klotz; Heinz Wiendl; Martin Stangel; Sven G Meuth
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-11

4.  Aging and therapy-related hypogammaglobulinemia causing pneumonia: An overlooked curable entity in the chaotic COVID-19 pandemic.

Authors:  Syed Ziauddin Ahmed Zaidi; Fatima Zia Zaidi; Nawal AlShehry; Abdul Rehman Zia Zaidi; Saleha Zia Zaidi; Syed Maaz Abdullah
Journal:  J Med Virol       Date:  2020-07-28       Impact factor: 20.693

5.  Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.

Authors:  Chunmei Ye; Weiwei Chen; Qi Gao; Yanxia Chen; Xiaolu Song; Sujie Zheng; Jinlin Liu
Journal:  Med Sci Monit       Date:  2021-07-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.